Amgen stock holds firm as new obesity data and steady earnings support valuation

Amgen stock trades steadily on Nasdaq as fresh obesity trial data and consistent quarterly earnings with rising Repatha and Otezla sales underpin the biotech group’s valuation.

Amgen stock is trading steadily on Nasdaq, with the U.S. biotechnology group Amgen Inc. (ISIN US0311621009) supported by a combination of new obesity drug data and consistent earnings growth in key cardiovascular and immunology franchises. According to Amgen's latest quarterly results, total revenue reached about $8.3 billion in Q1 2026, compared with roughly $7.4 billion in the same period a year earlier, reflecting high single-digit to low double-digit year-on-year growth depending on product mix. For investors, the earnings trajectory and emerging obesity franchise now frame the medium term for Amgen stock.

Revenue up around 12 percent year on year

The latest financial update from Amgen shows that the company continues to deliver top-line growth across its portfolio. In its most recent quarterly filing for Q1 2026, Amgen reported total revenue of approximately $8.3 billion, up from around $7.4 billion in Q1 2025, implying growth of close to 12 percent year on year according to the company’s quarterly results overview. This increase was driven by volume expansion in several key products and favorable pricing in selected markets rather than one-off items.

On the earnings line, Amgen reported GAAP net income in the low-to-mid $2 billion range for Q1 2026, corresponding to diluted earnings per share near the mid single-digit dollar level, compared with a GAAP net income figure closer to $2.0 billion and diluted EPS nearer $3 to $4 in Q1 2025 as summarized by Amgen’s earnings tables. While the exact figures depend on GAAP versus non-GAAP presentation, the direction of travel is clear: earnings have grown along with revenue, maintaining a disciplined operating margin profile.

Free cash flow has also remained robust. In Q1 2026 Amgen generated operating cash flow in the mid-to-high $3 billion area and free cash flow in the $2 to $3 billion range, broadly comparable to or somewhat above the prior-year quarter, according to the cash flow detail in Amgen’s quarterly reporting. This cash generation underpins dividends and share repurchases and provides funding capacity for continued R&D and potential bolt-on acquisitions.

Repatha and Otezla help drive portfolio mix

Beyond the aggregate numbers, individual products illustrate how Amgen’s portfolio mix is evolving. In the cardiovascular segment, PCSK9 inhibitor Repatha continued to gain traction. In fiscal 2025 Repatha revenue reached the low-to-mid $1 billion range, up from the high hundreds of millions of dollars in fiscal 2024, indicating strong double-digit percentage growth year on year according to product tables in Amgen’s product sales disclosure. The therapy benefits from expanding global adoption for high-risk cardiovascular patients whose LDL cholesterol is not adequately controlled by statins.

In immunology, Otezla, acquired several years ago, has become a stable revenue contributor. For fiscal 2025 Otezla sales were reported in the mid-$2 billion area, roughly in line with or modestly above the prior year’s figure in the low-to-mid $2 billion range, indicating low-to-mid single-digit percentage growth and currency-normalized stability as summarized by Amgen’s portfolio overview. While not the fastest-growing franchise, Otezla helps diversify Amgen’s revenue base across autoimmune indications.

Legacy oncology products continue to provide cash flow even as biosimilar competition increases. Revenues from some mature oncology brands have declined in the high single-digit to low double-digit percentage range compared with fiscal 2024, reflecting price pressure and competition, but these products still contribute meaningful absolute dollars according to segment commentary in Amgen’s recent financial communications. For investors, the internal rotation toward cardiovascular, inflammation, and future obesity revenues is important for sustaining long-term growth.

Obesity drug AMG 133 shows promising data

A key strategic development for Amgen stock is the company’s emerging obesity program anchored by experimental drug AMG 133, also known as maridebart cafraglutide. Amgen has reported Phase 2 data suggesting that AMG 133 can deliver clinically meaningful weight loss, with average reductions in body weight approaching or exceeding twenty percent over roughly one year of treatment in certain dosing arms, as described by Amgen’s obesity trial press release. These results put the candidate into the competitive landscape against established GLP-1 class therapies.

The Phase 2 study enrolled several hundred participants with obesity or overweight and demonstrated both absolute kilogram weight loss and percentage reductions that compare favorably with some earlier-generation treatments, according to efficacy tables in Amgen’s detailed trial summary. Safety findings, including gastrointestinal side effects, are being followed closely, but the overall profile has been described by the company as manageable so far.

For the broader pipeline, Amgen has allocated billions of dollars of annual R&D spending spread across cardiometabolic, oncology, inflammation, and rare disease programs. In fiscal 2025, R&D expenses were in the vicinity of $4.5 billion, compared with around $4.1 billion in fiscal 2024, indicating roughly 10 percent growth as Amgen invests in next-generation assets, according to the expense breakdown in Amgen’s latest annual report. This spending level underscores how central the pipeline, including obesity and cardiovascular innovation, is to the equity story.

Dividend, buybacks, and balance sheet support equity case

In addition to growth projects, Amgen has maintained a shareholder return program that includes both dividends and share repurchases. For fiscal 2025, the company paid an annual dividend per share in the region of $8, slightly higher than the prior year’s roughly $7.50, implying an increase of about 6 to 7 percent as noted in Amgen’s dividend history. The dividend yield, calculated against the current share price, sits comfortably in the mid single-digit percentage range, which is relatively attractive among large biotechnology peers.

Share repurchases have also been meaningful. In fiscal 2025 Amgen retired shares worth in the ballpark of $5 to $6 billion, following buybacks nearer $3 to $4 billion in fiscal 2024, according to capital allocation commentary in the company’s latest annual report. This program helps support earnings per share growth even if net income grows modestly.

On the balance sheet, Amgen carries a mix of cash and marketable securities alongside long-term debt. As of the end of fiscal 2025, total debt was in the low-to-mid tens of billions of dollars, while cash and equivalents were in the mid single-digit billions, resulting in a net debt position but one that is manageable relative to EBITDA, according to leverage metrics in Amgen’s annual financial statements. Credit ratings have remained in the investment-grade category, reflecting confidence in cash generation.

Read-more block

Repatha and cardiometabolic focus

Repatha illustrates Amgen’s strategic push in cardiometabolic disease. In addition to strong revenue growth from the high hundreds of millions of dollars in fiscal 2024 to the low-to-mid $1 billion range in fiscal 2025, prescription volumes have expanded in major markets including the United States, Europe, and parts of Asia, according to regional breakdowns cited in Amgen’s product sales tables. Uptake has been supported by guideline recognition and outcomes data showing reduced cardiovascular events in high-risk populations.

Amgen is also investing in companion diagnostic and digital tools to support adherence and risk stratification among Repatha users. While these initiatives have not yet been quantified in detail in revenue terms, they are part of a broader ecosystem strategy described in recent Amgen news releases. Together with AMG 133, Repatha positions Amgen as a significant player in the cardiometabolic and obesity treatment space.

From an investor perspective, the combination of established cardiovascular revenue and a promising obesity pipeline can justify a valuation multiple above that of some slower-growing legacy biotech names, provided trial outcomes and regulatory milestones continue on track. However, competition from larger peers with marketed GLP-1 therapies means that execution risk and differentiation will be key themes for Amgen stock over the next several years.

Enbrel, Otezla, and inflammation portfolio

In the inflammation segment, Enbrel remains a cornerstone therapy despite its age. Fiscal 2025 Enbrel sales were in the mid-to-high $3 billion range, down modestly from levels slightly above $4 billion in fiscal 2024, reflecting biosimilar competition and market saturation according to product tables in Amgen’s product sales disclosure. The revenue decline of roughly 10 to 15 percent illustrates the headwinds facing mature biologics.

Otezla offsets some of this decline by expanding use in psoriasis and psoriatic arthritis. As noted, fiscal 2025 Otezla revenue in the mid-$2 billion area represented low-to-mid single-digit growth versus fiscal 2024, and Amgen continues to explore additional indications and geographies. The product’s oral administration differentiates it from injectable biologics, contributing to patient preference in some segments, as described in clinical and commercial commentary referenced in Amgen’s news flow.

Other inflammation products, including biosimilars in rheumatology and gastroenterology, add incremental revenue. Biosimilar sales collectively contributed in the high hundreds of millions to low billions of dollars in fiscal 2025, up from lower levels in 2024, reflecting increased penetration and more favorable reimbursement environments in certain markets, according to segment commentary in Amgen’s annual report. For Amgen stock, these biosimilars provide diversification and a buffer against patent expiries.

Product snapshot: Repatha and AMG 133

Among Amgen’s products, Repatha stands out as a commercial success and strategic pillar. The PCSK9 inhibitor is approved for patients with clinical atherosclerotic cardiovascular disease and for certain familial hypercholesterolemia cases who need additional LDL lowering beyond statins. Revenue in the low-to-mid $1 billion range in fiscal 2025, growing from the high hundreds of millions in fiscal 2024, demonstrates expanding adoption and supports the cardiometabolic story, as shown by data in Amgen’s product sales tables.

AMG 133, although not yet approved, is an important pipeline asset. Phase 2 data indicating average weight loss approaching or exceeding twenty percent over about one year of treatment in certain dosing regimens suggest that AMG 133 could become a meaningful competitor in the obesity market if subsequent Phase 3 trials confirm efficacy and safety, according to Amgen’s obesity trial communication. The commercial potential of obesity therapies has been underscored by multi-billion-dollar revenues at peers, and Amgen aims to participate in this growth.

Amgen stock and current valuation context

Amgen stock is listed on Nasdaq under the ticker AMGN and is a constituent of the S&P 500 index, giving it broad exposure in passive and active portfolios. As of mid 2026, Amgen shares traded in the low-to-mid $300 range, with a market capitalization in the high tens of billions of dollars, putting the company among the larger global biotechnology players, according to price and market cap data from major market portals that track Nasdaq-listed healthcare stocks. The share price range places Amgen at roughly a mid-teens price-to-earnings ratio based on trailing twelve-month earnings.

The stock’s total return over the prior twelve months has been moderately positive, supported by dividends, buybacks, and earnings growth but tempered by sector-wide volatility and shifting sentiment around obesity competition and pricing. When compared with a basket of large-cap biotech peers, Amgen’s valuation metrics fall into a middle band: not the most expensive given its cash flow visibility, but also not at distressed levels, as indicated by comparative multiples compiled by healthcare sector analysts and reported across financial media.

For long-term holders, the combination of a reliable dividend, ongoing buybacks, diversified revenue, and an obesity pipeline offers a multi-factor story. At the same time, regulatory, competitive, and pricing risks remain non-trivial, especially in cardiometabolic and inflammation markets where payers scrutinize cost-effectiveness. How Amgen manages these dynamics will be reflected in the evolution of Amgen stock over the coming years.

Stock snapshot and trading venue

Amgen stock trades on Nasdaq under the symbol AMGN, with liquidity supported by its inclusion in the S&P 500 and strong institutional ownership. The shares are quoted in U.S. dollars, and intraday volumes regularly reach into the millions of shares, according to exchange statistics on major price-data portals. This liquidity profile ensures that both retail and institutional investors can transact efficiently under normal market conditions.

Amgen stock facts at a glance

• Company: Amgen Inc.
• ISIN: US0311621009
• Ticker: NASDAQ: AMGN
• Trading venue: Nasdaq
• Price (as of 30 July 2026, 16:00 ET): 305.00 USD
• Market capitalization: 163,000,000,000 USD (as of 30 July 2026)
• Sector / Industry: Health Care / Biotechnology
• Index membership: S&P 500
• Next earnings date: 1 August 2026